BIOMAT Database Logo BIOMAT Database Logo

Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy. 2023

Claudia Maria Trombetta, and Serena Marchi, and Margherita Leonardi, and Chiara Coppola, and Linda Benincasa, and Maria Giovanna Marotta, and Nicola Buonvino, and Piet Maes, and Angela Stufano, and Daniela Pontrelli, and Violetta Iris Vasinioti, and Alessandro Manenti, and Michele Camero, and Emanuele Montomoli, and Nicola Decaro, and Piero Lovreglio
Department of Molecular and Developmental Medicine, University of Siena, via Aldo Moro 2, Siena 53100, Italy. Electronic address: trombetta@unisi.it.

The Omicron variant is the most divergent, displaying more mutations than previous SARS-CoV-2 variants, particularly in the gene that encodes the spike protein. This study aimed to assess the persistence of neutralizing antibodies towards the SARS-CoV-2 Omicron sublineages (BA.2, BA.5, BQ.1, XBB and XBB1.5) six months after the third dose in different vaccination regimens. Subjects who received 3 doses of mRNA vaccine retained their neutralization activity against BA.2 and BA.5, even though 56.3% and 66.7% showed a ≥ 2-fold reduction in the neutralizing antibody titre, respectively. Subjects who had received the adenovirus-based vaccine plus a booster dose of mRNA vaccine retained their neutralization activity especially against BA.2. With regard to BQ.1, XBB and XBB.1.5, the majority of the subjects showed a ≥ 2-fold reduction in neutralizing antibody titre, with the greatest evasion being observed in the case of XBB. Overall, our results provide further evidence that triple homologous/heterologous vaccination and hybrid immunity result in detectable neutralizing antibodies against the ancestral virus; however, emerging Omicron sublineages, such as XBB and XBB.1.5, show a great evasive capacity, which compromises the effectiveness of current COVID-19 vaccines.

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D007558 Italy A country in southern Europe, a peninsula extending into the central Mediterranean Sea, northeast of Tunisia. The capital is Rome. Sardinia
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000086382 COVID-19 A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. In severe cases, a myriad of coagulopathy associated symptoms often correlating with COVID-19 severity is seen (e.g., BLOOD COAGULATION; THROMBOSIS; ACUTE RESPIRATORY DISTRESS SYNDROME; SEIZURES; HEART ATTACK; STROKE; multiple CEREBRAL INFARCTIONS; KIDNEY FAILURE; catastrophic ANTIPHOSPHOLIPID ANTIBODY SYNDROME and/or DISSEMINATED INTRAVASCULAR COAGULATION). In younger patients, rare inflammatory syndromes are sometimes associated with COVID-19 (e.g., atypical KAWASAKI SYNDROME; TOXIC SHOCK SYNDROME; pediatric multisystem inflammatory disease; and CYTOKINE STORM SYNDROME). A coronavirus, SARS-CoV-2, in the genus BETACORONAVIRUS is the causative agent. 2019 Novel Coronavirus Disease,2019 Novel Coronavirus Infection,2019-nCoV Disease,2019-nCoV Infection,COVID-19 Pandemic,COVID-19 Pandemics,COVID-19 Virus Disease,COVID-19 Virus Infection,Coronavirus Disease 2019,Coronavirus Disease-19,SARS Coronavirus 2 Infection,SARS-CoV-2 Infection,Severe Acute Respiratory Syndrome Coronavirus 2 Infection,COVID19,2019 nCoV Disease,2019 nCoV Infection,2019-nCoV Diseases,2019-nCoV Infections,COVID 19,COVID 19 Pandemic,COVID 19 Virus Disease,COVID 19 Virus Infection,COVID-19 Virus Diseases,COVID-19 Virus Infections,Coronavirus Disease 19,Disease 2019, Coronavirus,Disease, 2019-nCoV,Disease, COVID-19 Virus,Infection, 2019-nCoV,Infection, COVID-19 Virus,Infection, SARS-CoV-2,Pandemic, COVID-19,SARS CoV 2 Infection,SARS-CoV-2 Infections,Virus Disease, COVID-19,Virus Infection, COVID-19
D000086402 SARS-CoV-2 A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis. 2019 Novel Coronavirus,COVID-19 Virus,COVID19 Virus,Coronavirus Disease 2019 Virus,SARS Coronavirus 2,SARS-CoV-2 Virus,Severe Acute Respiratory Syndrome Coronavirus 2,Wuhan Coronavirus,Wuhan Seafood Market Pneumonia Virus,2019-nCoV,2019 Novel Coronaviruses,COVID 19 Virus,COVID-19 Viruses,COVID19 Viruses,Coronavirus 2, SARS,Coronavirus, 2019 Novel,Coronavirus, Wuhan,Novel Coronavirus, 2019,SARS CoV 2 Virus,SARS-CoV-2 Viruses,Virus, COVID-19,Virus, COVID19,Virus, SARS-CoV-2,Viruses, COVID19
D000086663 COVID-19 Vaccines Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19. 2019 Novel Coronavirus Vaccine,2019 Novel Coronavirus Vaccines,2019-nCoV Vaccine,2019-nCoV Vaccines,COVID 19 Vaccine,COVID-19 Vaccine,COVID-19 Virus Vaccine,COVID-19 Virus Vaccines,COVID19 Vaccine,COVID19 Vaccines,COVID19 Virus Vaccine,COVID19 Virus Vaccines,Coronavirus Disease 2019 Vaccine,Coronavirus Disease 2019 Vaccines,Coronavirus Disease 2019 Virus Vaccine,Coronavirus Disease 2019 Virus Vaccines,Coronavirus Disease-19 Vaccine,Coronavirus Disease-19 Vaccines,SARS Coronavirus 2 Vaccines,SARS-CoV-2 Vaccine,SARS-CoV-2 Vaccines,SARS2 Vaccine,SARS2 Vaccines,2019 nCoV Vaccine,2019 nCoV Vaccines,COVID 19 Vaccines,COVID 19 Virus Vaccine,COVID 19 Virus Vaccines,Coronavirus Disease 19 Vaccine,Coronavirus Disease 19 Vaccines,SARS CoV 2 Vaccine,SARS CoV 2 Vaccines,Vaccine, 2019-nCoV,Vaccine, COVID 19,Vaccine, COVID-19,Vaccine, COVID-19 Virus,Vaccine, COVID19,Vaccine, COVID19 Virus,Vaccine, Coronavirus Disease-19,Vaccine, SARS-CoV-2,Vaccine, SARS2,Vaccines, 2019-nCoV,Vaccines, COVID-19,Vaccines, COVID-19 Virus,Vaccines, COVID19,Vaccines, COVID19 Virus,Vaccines, Coronavirus Disease-19,Vaccines, SARS-CoV-2,Vaccines, SARS2,Virus Vaccine, COVID-19,Virus Vaccine, COVID19,Virus Vaccines, COVID-19,Virus Vaccines, COVID19
D000087503 mRNA Vaccines Vaccines formulated with recombinant mRNAs which are taken up by the host cells that translate the mRNA and present the translated proteins to the immune system as antigens in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigen. Messenger RNA Vaccines,Naked RNA Vaccines,RNA Vaccines,Self-Amplifying RNA Vaccine,Trans Amplifying RNA Vaccine,saRNA Vaccine,taRNA Vaccine,RNA Vaccine,mRNA Vaccine,RNA Vaccine, Self-Amplifying,Self Amplifying RNA Vaccine,Vaccine, RNA,Vaccine, Self-Amplifying RNA,Vaccine, mRNA,Vaccine, saRNA,Vaccine, taRNA,Vaccines, RNA
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D057134 Antibodies, Neutralizing Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus. Neutralizing Antibodies,Antibody, Neutralizing,Neutralizing Antibody

Related Publications

Claudia Maria Trombetta, and Serena Marchi, and Margherita Leonardi, and Chiara Coppola, and Linda Benincasa, and Maria Giovanna Marotta, and Nicola Buonvino, and Piet Maes, and Angela Stufano, and Daniela Pontrelli, and Violetta Iris Vasinioti, and Alessandro Manenti, and Michele Camero, and Emanuele Montomoli, and Nicola Decaro, and Piero Lovreglio
Humoral immune response after different SARS-CoV-2 vaccination regimens.
January 2022, BMC medicine,
Claudia Maria Trombetta, and Serena Marchi, and Margherita Leonardi, and Chiara Coppola, and Linda Benincasa, and Maria Giovanna Marotta, and Nicola Buonvino, and Piet Maes, and Angela Stufano, and Daniela Pontrelli, and Violetta Iris Vasinioti, and Alessandro Manenti, and Michele Camero, and Emanuele Montomoli, and Nicola Decaro, and Piero Lovreglio
Immune profile of healthcare professionals six months after vaccination or exposure to SARS-CoV-2 in Angola.
January 2023, Health science reports,
Claudia Maria Trombetta, and Serena Marchi, and Margherita Leonardi, and Chiara Coppola, and Linda Benincasa, and Maria Giovanna Marotta, and Nicola Buonvino, and Piet Maes, and Angela Stufano, and Daniela Pontrelli, and Violetta Iris Vasinioti, and Alessandro Manenti, and Michele Camero, and Emanuele Montomoli, and Nicola Decaro, and Piero Lovreglio
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
April 2022, Nature,
Claudia Maria Trombetta, and Serena Marchi, and Margherita Leonardi, and Chiara Coppola, and Linda Benincasa, and Maria Giovanna Marotta, and Nicola Buonvino, and Piet Maes, and Angela Stufano, and Daniela Pontrelli, and Violetta Iris Vasinioti, and Alessandro Manenti, and Michele Camero, and Emanuele Montomoli, and Nicola Decaro, and Piero Lovreglio
Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination.
February 2023, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Claudia Maria Trombetta, and Serena Marchi, and Margherita Leonardi, and Chiara Coppola, and Linda Benincasa, and Maria Giovanna Marotta, and Nicola Buonvino, and Piet Maes, and Angela Stufano, and Daniela Pontrelli, and Violetta Iris Vasinioti, and Alessandro Manenti, and Michele Camero, and Emanuele Montomoli, and Nicola Decaro, and Piero Lovreglio
Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.
July 2022, Signal transduction and targeted therapy,
Claudia Maria Trombetta, and Serena Marchi, and Margherita Leonardi, and Chiara Coppola, and Linda Benincasa, and Maria Giovanna Marotta, and Nicola Buonvino, and Piet Maes, and Angela Stufano, and Daniela Pontrelli, and Violetta Iris Vasinioti, and Alessandro Manenti, and Michele Camero, and Emanuele Montomoli, and Nicola Decaro, and Piero Lovreglio
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
August 2022, bioRxiv : the preprint server for biology,
Claudia Maria Trombetta, and Serena Marchi, and Margherita Leonardi, and Chiara Coppola, and Linda Benincasa, and Maria Giovanna Marotta, and Nicola Buonvino, and Piet Maes, and Angela Stufano, and Daniela Pontrelli, and Violetta Iris Vasinioti, and Alessandro Manenti, and Michele Camero, and Emanuele Montomoli, and Nicola Decaro, and Piero Lovreglio
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
November 2022, Science (New York, N.Y.),
Claudia Maria Trombetta, and Serena Marchi, and Margherita Leonardi, and Chiara Coppola, and Linda Benincasa, and Maria Giovanna Marotta, and Nicola Buonvino, and Piet Maes, and Angela Stufano, and Daniela Pontrelli, and Violetta Iris Vasinioti, and Alessandro Manenti, and Michele Camero, and Emanuele Montomoli, and Nicola Decaro, and Piero Lovreglio
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine.
January 2022, Vaccines,
Claudia Maria Trombetta, and Serena Marchi, and Margherita Leonardi, and Chiara Coppola, and Linda Benincasa, and Maria Giovanna Marotta, and Nicola Buonvino, and Piet Maes, and Angela Stufano, and Daniela Pontrelli, and Violetta Iris Vasinioti, and Alessandro Manenti, and Michele Camero, and Emanuele Montomoli, and Nicola Decaro, and Piero Lovreglio
Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages.
January 2023, International journal of medical sciences,
Claudia Maria Trombetta, and Serena Marchi, and Margherita Leonardi, and Chiara Coppola, and Linda Benincasa, and Maria Giovanna Marotta, and Nicola Buonvino, and Piet Maes, and Angela Stufano, and Daniela Pontrelli, and Violetta Iris Vasinioti, and Alessandro Manenti, and Michele Camero, and Emanuele Montomoli, and Nicola Decaro, and Piero Lovreglio
Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease.
July 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
Copied contents to your clipboard!